Menu
Our comprehensive market study provides an insightful overview of the High-Content Imaging (HCI) landscape, focusing on the current status and potential developments in early drug discovery. The survey was conducted from November to mid-December 2023 and targeted a global audience of healthcare researchers, biotech experts, large pharmaceutical companies, and academic institutions.
The goal was to gain a comprehensive view of HCI applications and advances in AI support related to HCI. The survey targeted experienced professionals and scientists in the field and gathered interesting information on current application practices, investment plans, and attitudes toward outsourcing.
In addition, the importance of HCI in achieving research goals was explored, and an overview of the integration and importance of HCI in early research projects was provided. The results will illuminate prevailing trends, highlight emerging challenges and growth opportunities, and provide insights to help organizations tailor and refine strategic approaches to deploying HCI in research environments.
With the information gained from the survey, industry professionals will be better equipped to make forward-looking, strategic decisions about meaningful HCI applications and deployments in order to derive maximum benefit from the innovative use of HCI in early drug discovery.
The survey results highlight the participation of a wide range of industry-leading professionals, predominantly senior scientists and senior managers with budget authority, underscoring the depth of expertise and decision-making influence represented.
The survey was mainly answered by professionals from the pharmaceutical and biotechnology industries, with a significant contribution from contract research organizations, indicating a strong industrial research focus and less academic participation.
The survey featured respondents with extensive HCI experience, the majority with more than 10 years in the field, indicating a deep level of expertise among the participants.
Usage Terms and Disclaimer
By purchasing this report, you agree to the following copyright terms and conditions of CELLIMA Scientific Services GmbH (hereinafter referred to as “CELLIMA”). These terms constitute a legally binding agreement between you (the purchaser) and CELLIMA.You are granted a non-transferable, non-exclusive license to use this report within your organization. Any form of distribution, transmission or provision of the report – electronically, physically or otherwise – outside your organization is strictly prohibited without the prior written consent of CELLIMA. If you wish to distribute or make available the contents of this report outside the boundaries of your organization, you must first obtain the express written permission of CELLIMA. Failure to obtain such permission may be considered a violation of this agreement.Violation of this Agreement may result in legal action, including, but not limited to, civil action and/or criminal prosecution under applicable law. CELLIMA reserves the right to enforce its copyrights and to strictly protect its intellectual property. This agreement is subject to the law of the jurisdiction in which CELLIMA is registered and will be interpreted in accordance with that law, without application of the principles of conflict of laws.
CELLIMA has exercised due diligence in compiling and preparing this report, based on information obtained from individuals within the surveyed companies. CELLIMA has not verified the accuracy of this information, nor has it confirmed the authority of the interviewees to disclose information to CELLIMA.
CELLIMA explicitly disclaims all warranties related to this report, including any warranty of merchantability and/or fitness for a particular purpose, any warranty of performance, and any warranty that might otherwise arise from the course of dealing or usage of trade. No warranty, either expressed or implied, is made regarding the use of this report. Under no circumstances shall CELLIMA be liable for any indirect, special, incidental, or consequential damages or for any lost profits, business interruption, or related expenses arising from the use of this report, including, but not limited to, those resulting from inaccuracies in the data contained within.